Sanovas CEO Larry Gerrans Featured at BayBio’s ‘Fundraising in Troubled Times’
SAUSALITO, Calif., Jan. 24, 2012 — Sanovas CEO Larry Gerrans will participate in a panel titled “Fundraising in Troubled Times” as part of BayBio’s Life Sciences Series on Thursday, Jan. 26 at 8 a.m. in Palo Alto. The event will take place at the Silicon Valley offices of DLA Pip…
Science, Government and Industry Converge in National Call to Action on Lung Cancer
SAUSALITO, Calif., Aug. 11, 2011 — The New England Journal of Medicine’s recent publication of the landmark National Lung Screening Trial (NLST), along with two congressional initiatives and an industry report, beacon a much brighter future for Lung Cancer patients.
Forty-three milli…
REDDING, Calif., June 21, 2011 — “In these modern times of ‘advanced medical technology’ and better diagnostics, our health conditions are not getting better. Statistical reports from Centers for Disease Control and Prevention indicate chronic diseases are still preval…
Health care strategy consultant, blogger and speaker David E. Williams leverages Twitter followers to forecast four main health care trends for 2011
BOSTON, Dec. 21, 2010 — David E. Williams, co-founder of MedPharma Partners – http://www.mppllc.com – and author of the Health Bus…
Inactivity Does Not Cause Obesity: Study Confirms Dr. Hanan Polansky’s Starved Gene Theory
ROCHESTER, N.Y., July 15, 2010 — According to a recent longitudinal study in children, inactivity does not lead to fatness! Moreover, the authors concluded that fatness is driving inactivity, and not the other way around. The authors noted that this “reverse causality” explains t…
Treatment for Hepatitis C with Antiviral Supplement Gene-Eden, a New Opportunity?
ROCHESTER, N.Y., May 13, 2010 — A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load in people infected with the virus.
According to Adrian Di Bisceglie, MD, chair and professor of internal medicine at S…
SAN DIEGO, March 17, 2010 — In his newest book, “Overlooked Causes and the Prevention: Cancer, Cardiovascular Heart Disease, Multiple Sclerosis” (published by AuthorHouse), author Arthur Douglass Alexander III exposes, delineates and documents the sometimes overlooked and o…
INV102 Asthma Product Discussed at the European Respiratory Society
SAN FRANCISCO, Sept. 22, 2009 — A symposium was held last week at the European Respiratory Society’s annual meeting in Vienna, Austria entitled “Beta-blockers may now be beneficial in asthma and COPD.”
“It is remarkable how far Inverseon’s asthma program has a…
MIQS Software Again Recognized by the Computerworld Honors Program; Wins Top Award
MIQS Recognized With Global Information Technology Award That Pays Tribute to Individuals and Organizations That Use Information Technology to Benefit Society
BOULDER, Colo., June 3, 2009 — MIQS, a Boulder-based electronic medical information software (EMR) company, has been recognized a…
Inverseon’s Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
SAN FRANCISCO, Jan. 14, 2009 — Inverseon, Inc. (http://www.inverseon.com) announces the receipt of a notice of allowance from the United States Patent Office covering its oral product INV102 for asthma. Additionally, a comment highlighting Inverseon’s clinical asthma study was publ…
